Transected axons fail to regrow spontaneously across severe tissue lesions in the mature mammalian central nervous system (CNS). Potential mechanisms include: (i) reduced intrinsic growth capacity of mature CNS neurons [1] [2] [3] ; (ii) absence of external growth stimulating and supporting factors 1, 4, 5 ; and (iii) presence of external inhibitory factors associated with myelin 6,7 , fibrotic tissue 8 or astrocytic scars 9 . Alleviating cellular and molecular mechanisms underlying axon regeneration failure is fundamental to improving CNS repair after traumatic injury, stroke or degenerative disease.
1
Transected axons fail to regrow spontaneously across severe tissue lesions in the mature mammalian central nervous system (CNS). Potential mechanisms include: (i) reduced intrinsic growth capacity of mature CNS neurons [1] [2] [3] ; (ii) absence of external growth stimulating and supporting factors 1, 4, 5 ; and (iii) presence of external inhibitory factors associated with myelin 6, 7 , fibrotic tissue 8 or astrocytic scars 9 . Alleviating cellular and molecular mechanisms underlying axon regeneration failure is fundamental to improving CNS repair after traumatic injury, stroke or degenerative disease.
Astrocytic scars have been regarded as barriers to CNS axon regrowth since the mid-twentieth century on the basis of their appearance and early reports that attenuating astrocytic scar formation enabled spontaneous axon regrowth 10, 11 . Although axon-growth-promoting effects of early scar attenuators proved illusory, reports correlating failed axon regrowth with presence of mature astrocytes 12 or astrocytic scars 9 , plus evidence that astrocytes produce chondroitin sulfate proteoglycans (CSPGs) that inhibit axon growth in vitro 9 , led to the widespread view that astrocytic scars are critical inhibitors of CNS axons and that nullifying this inhibition will lead to spontaneous axon regeneration.
Here we tested the hypothesis that astrocytic scar formation plays a causal role in the failure of transected mature CNS axons to regenerate across severe tissue lesions. We used multiple transgenic loss-of-function strategies to ablate scar-forming astrocytes, genetically attenuate scar-forming astrocytes or to ablate chronic astrocytic scars after severe SCI in adult mice. We quantified the effects of these manipulations on (i) spontaneous regeneration of three major types of CNS axons; (ii) total CSPG levels; (iii) genomewide expression by astrocytes and non-astrocytes in SCI lesions of molecules associated with axon growth; and (iv) axon regeneration stimulated by conditioning lesions plus delivery via synthetic hydrogel depots of known axon-required growth factors missing from SCI lesions.
No axon regrowth after preventing scars
We first determined effects of preventing astrocytic scar formation on the potential for spontaneous unstimulated axon regeneration through severe CNS lesions. After focal traumatic tissue damage, CNS lesions comprise central areas of non-neural lesion core tissue surrounded by narrow astrocytic scar borders 13, 14 . Astrocytic scar formation is complete by two weeks after adult murine SCI and is critically dependent on astrocyte proliferation and STAT3 signalling [15] [16] [17] [18] . We prevented astrocyte scar formation with two loss-of-function transgenic mouse models that either selectively kill proliferating scar-forming astrocytes 15, 16 or delete STAT3 signalling selectively from astrocytes 17, 18 , referred to respectively as TK+GCV or STAT3-CKO mice (Supplementary Information).
After severe crush SCI, wild-type mice formed dense astrocytic scars by two weeks that persisted for eight weeks, whereas TK+GCV and STAT3-CKO mice failed to form scars and instead exhibited larger areas of non-neural tissue around lesion centres that were essentially devoid of astrocytes from two to eight weeks after SCI (Fig. 1a-d , Extended Data Fig. 1 and Supplementary Information).
Effects of preventing astrocyte scar formation on axon regeneration were quantified in three axonal systems: (i) descending corticospinal tract (CST); (ii) ascending sensory tract (AST); and (iii) descending serotonergic (5HT) tract, visualized either by axonal tract tracing or immunohistochemistry (Fig. 1c , e-i and Supplementary Information). As expected after severe SCI in adult wild-type mice, transected CST and AST axons both exhibited moderate dieback away from lesion centres (Fig. 1c , e, g, h). Preventing astrocytic scar formation in either TK+GCV or STAT3-CKO mice failed to result in spontaneous regrowth of transected CST or AST axons through SCI lesions, and instead significantly increased axonal dieback (Fig. 1c, e, g, h) . As expected 19, 20 , transected 5HT axons exhibited little dieback from lesion centres (Fig. 1f, i) . Preventing scar formation in TK+GCV or STAT3-CKO mice did not exacerbate dieback of 5HT axons.
Nevertheless, although many 5HT axons remained in lesion centres devoid of astrocytes, they also failed to regrow (Fig. 1f, i) .
Thus, in spite of the essential absence of scar-forming astrocytes from SCI lesions for eight weeks after SCI in TK + GCV mice or STAT3-CKO mice, there was no spontaneous regeneration of transected CST, AST or 5HT axons through the lesions. This regrowth failure was particularly apparent for AST and 5HT axons, the axonal tips of which were often present along or within large areas devoid of astrocytes but did not regrow spontaneously through such areas (Fig. 1e, f) .
No axon regrowth after removing chronic scars
Acute astrocytic scar formation restricts inflammation and preserves neural tissue [14] [15] [16] [17] [18] . It has been proposed that after inflammation has resolved, chronic astrocytic scars are expendable and detrimental because they continually prevent axon regeneration. To test this hypothesis, we ablated chronic astrocytic scars five weeks after SCI with genetically targeted diphtheria toxin receptor and ultra-low doses of diphtheria toxin 21 ( Fig. 2 and Supplementary Information). Distribution and specificity of targeting to mature astrocytic scars was verified with the genetic reporter tdTomato (Fig. 2b , Extended Data Fig. 1c and Supplementary Information). GFAP immunohistochemistry verified efficient removal of chronic astrocytic scars (Fig. 2c) . Axon quantitation ten weeks after SCI showed that transected CST, AST or 5HT axons all failed to regrow spontaneously through areas depleted of chronic astrocytic scars (Fig. 2d-i) . Again, this failure was particularly notable for AST and 5HT axons in or along areas devoid of scarforming astrocytes that did not regrow through these areas (Fig. 2e, f) . We also ablated chronic astrocytic scars and adjacent astrocytes over larger areas to reach 'died-back' CST and AST axons, but this approach caused pronounced tissue degeneration and large lesions (Extended Data Fig. 1e ) that contained essentially no detectable CST, AST or 5HT axons. These findings show that ablating chronic astrocytic scars fails to result in spontaneous regrowth of CST, AST or 5HT axons through SCI lesions, and that chronic astrocytic scars remain critical for sustaining tissue integrity.
Multicellular CSPG production
We next looked for molecular mechanisms that might explain why ablating or attenuating astrocytic scars failed to enable spontaneous axon regrowth through severe lesions. CSPGs produced by astrocytic scars are regarded as the principal inhibitors of axon regeneration 9 . Total CSPG levels determined by dot blot with CS56 antibody 9, 22 were, as expected 9 , significantly higher in our wild-type SCI lesions, but were not significantly reduced by transgenic ablation or disruption of astrocytic scar formation (Fig. 3a) . Because diverse cells in SCI lesions including pericytes, fibroblast lineage cells and inflammatory cells 13 can produce CSPGs 23 , we examined cellular production of CSPG and GFAP and quantified immunohistochemically stained tissue areas. In SCI lesions of TK+GCV and STAT3-CKO mice, GFAP area was significantly reduced in both grey and white matter compared with wild type, whereas CSPG area was not significantly reduced in lesion core tissue or in regions of ablated astrocytic scars, which were filled with CSPG-positive, GFAP-negative cells (Figs 3b,c, Extended Data Fig. 2 and Supplementary Information). These findings show that nonastrocyte cells in SCI lesions produce substantive amounts of CSPGs CST, n = 6 mice; AST and 5HT, n = 5 mice; *P < 0.05 versus wild type (ANOVA with Newman-Keuls). and that preventing astrocytic scar formation fails to reduce total CSPG production in SCI lesions.
Genomic dissection of SCI lesions
Numerous molecules attract, repel, support or inhibit axon growth during development, and many of these are present in CNS lesions 7, 24, 25 . To look broadly at molecules produced by astrocytes or non-astrocyte cells in SCI lesions that might affect axon regrowth, we conducted genomewide RNA sequencing of astrocyte-specific ribosome-associated RNA (ramRNA) precipitated via a haemagglutinin tag 26 transgenically targeted to either wild-type or STAT3-CKO astrocytes, and nonprecipitated (flow-through) RNA deriving from non-astrocyte cells in the same tissue samples (Fig. 4 , Extended Data Fig. 3 and Supplementary Information).
At two weeks after SCI, astrocytes and non-astrocyte cells in SCI lesions exhibited significantly altered expression of many genes in both wild-type and STAT3-CKO mice, and wild-type astrocytes exhibited expected known changes 27 (Extended Data Fig. 4a -d and Supplementary Information). Notably, 63% of genes significantly regulated by wild-type astrocytes were not significantly altered by STAT3-CKO astrocytes after SCI, and STAT3-CKO SCI astrocyte transcriptomes clustered more similarly towards uninjured astrocytes than towards wild-type SCI astrocytes (Fig. 4c, d ).
We analysed 59 molecules reported to negatively or positively modulate axon growth in SCI lesions (Extended Data Table 1 ). In SCI lesions from wild-type mice, both astrocytes and non-astrocyte cells expressed a majority not only of 28 known axon inhibitors, including specific CSPGs, ephrins, netrins, neuropillins, plexins, slits and others, but also a majority of 31 known axon permissive molecules, including specific CSPGs, laminins, syndecans, glypicans, decorin and others (Fig. 4e) . Notably, both astrocytes and non-astrocytes downregulated more axon inhibitory molecules than were upregulated, and upregulated more than three times the number of axon-permissive molecules than were downregulated. Preventing astrocytic scar formation in STAT3-CKO mice did not significantly decrease the expression by astrocytes or non-astrocytes of a single reported inhibitor, whereas eleven were upregulated, and significantly increased the expression of two permissive molecules, and decreased three, compared to wild-type SCI (Fig. 4e ).
In agreement with our immunoblot and immunohistochemical CSPG findings (above), various individual CSPG ramRNAs were expressed by both astrocytes and non-astrocyte cells in SCI lesions (Fig. 4e) . Interestingly, aggrecan, the prototypical CSPG used in axon growth inhibition studies in vitro 9, 28 , was not detectably expressed by scar-forming astrocytes at either the ramRNA or immunohistochemistry of protein levels ( Fig. 4e and Extended Data Fig. 5a ). Other axon-inhibitory CSPGs, brevican, neurocan, versican and phosphacan, were all expressed by both scar-forming astrocytes and nonastrocyte cells in SCI lesions as revealed by RNA analysis (Fig. 4e ) and confirmed by immunohistochemistry of protein for brevican and neurocan (Extended Data Figs 5b and 6a).
CSPGs are diverse with respect to inhibiting or supporting axon growth at both protein and sugar-epitope levels 29, 30 . Of the five growth-inhibitory CPSGs, wild-type scar-forming astrocytes increased above normal only versican ramRNA, and significantly decreased neurocan and phosphacan (Fig. 4e) . In contrast, ramRNAs of two axon-growth-supportive CSPGs, Cspg4 (NG2) and Cspg5 (neuroglycan C) (Extended Data Table 1 ), were significantly upregulated by scar-forming astrocytes (Fig. 4e) and both NG2 and CSPG5 clearly decorated scar-forming astrocytes, as revealed by immunohistochemistry (Extended Data Fig. 6b, c) .
Our genomic findings show that: (i) STAT3-CKO prevents or attenuates a majority of genome-wide changes in astrocytes associated with astrogliosis and scar formation in wild-type mice; (ii) astrocytes and non-astrocyte cells in SCI lesions express a large, diverse mix of axon inhibitory and permissive molecules; (iii) non-astrocyte cells in SCI lesions substantively express CSPGs; (iv) preventing astrocyte scar formation with STAT3-CKO does not reduce expression of CSPGs or other inhibitory molecules in SCI lesions; (v) scar-forming astrocytes upregulate and substantively express axon-growth-supporting CSPGs, indicating that CS56 immune detection of total CSPG levels 22 need not indicate a purely axon-inhibitory environment; and (vi) scar-forming astrocytes and non-astrocyte cells in SCI lesions upregulate multiple axon-growth-permissive matrix molecules, including laminins.
Axon regrowth in spite of scar formation
We next stimulated axon growth after SCI in the presence or absence of astrocytic scar formation. Developing axons do not grow by default but require stimulatory cues 31 . This requirement may apply also to regrowth of transected mature axons. Some transected mature AST axons can be stimulated to regrow in severe SCI lesions by activating neuron intrinsic growth programs with peripheral conditioning lesions [32] [33] [34] , and this regrowth can be significantly augmented by cell grafts that provide supportive matrix plus the neurotrophic factors NT3 and BDNF that attract AST axon growth during development 35 . We noted the essential absence of Nt3 and Bdnf expression in our wild-type SCI lesions, combined with expression of permissive matrix molecules including laminins known to support developing AST axons 36 ( Fig. 4e and Extended Data Table 1 ). We therefore tested effects of conditioning lesions plus local delivery of NT3 and BDNF on AST axon regeneration stimulated in the presence or absence of astrocyte scar formation ( Fig. 5 and Extended Data Figs 7-9). Because cell grafts modify astrocytic scars 35 and provide permissive substrates for regrowing axons, we delivered NT3 and BDNF via synthetic hydrogel depots that do not modify astrocytic scar formation and provide prolonged neurotrophin delivery [37] [38] [39] ( Fig. 5d ; Supplementary Information). No AST fibres regrew past astrocytic scars into lesion cores after SCI alone or with hydrogel without growth factors (Fig. 5a , j and 
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Extended Data Fig. 7c ). Small numbers of AST axons regrew into lesion cores in mice with SCI plus conditioning lesions alone, or SCI plus NT3 and BDNF without conditioning lesions (Fig. 5j, k and Extended Data Fig. 7c ). By contrast, mice receiving both conditioning lesions plus NT3 and BDNF exhibited robust axon regrowth through and beyond astrocytic scars, and the number of axon intercepts counted at lesion centres averaged over 45% of that in intact sensory tracts 3 mm proximal to lesions (Fig. 5b , j, k and Extended Data Fig. 7c) . Remarkably, these stimulated AST axons regrew profusely through, and past, dense astrocyte scars, and in spite of substantial CSPG (Fig. 5b, e-g, Extended Data Figs 7b, c and 8 ). AST axons stimulated to regrow in SCI lesions were thin and uniformly tracked along laminin surfaces, turning and even reversing direction along these surfaces as expected of regenerating axons 40 , whereas AST axons in intact gracile-cuneate tracts were coarsely beaded and were not in direct contact with laminin ( Fig. 5h and Extended Data Fig. 9a-f) . Hydrogel delivery of anti-CD29 laminin-integrin function-blocking antibodies 36 together with NT3 and BDNF significantly reduced AST axon regrowth in lesion cores by 73%, demonstrating that laminin interactions were critical for stimulated AST axon regrowth (Fig. 5i, j , Extended Data Fig. 9g-i and Supplementary Information) . Lastly, preventing astrocyte scar formation did not augment AST axon regrowth stimulated by conditioning lesions plus NT3 and BDNF, but instead completely prevented, or significantly attenuated, axon regrowth in TK + GCV mice and STAT3-CKO mice, respectively (Fig. 5c, j, k) , demonstrating that astrocytic scar formation aids, rather than inhibits appropriately stimulated AST axon regeneration after SCI.
Discussion
Our findings show that contrary to prevailing dogma, astrocytic scar formation is not a principal cause for the failure of injured mature CNS axons to regrow across severe CNS lesions and that scar-forming astrocytes permit and support robust amounts of appropriately stimulated CNS axon regeneration. Although our observations with stimulated AST axon regeneration needs extension to other axonal systems, our findings are consistent with evidence that: (i) astrocytes can support growth of different CNS axons in vivo during development 41, 42 or after mature CNS injury 19, 43 ; (ii) genetic activation of axonal growth programs by mature neurons leads to axon regeneration across CNS lesions only when scar-forming astrocyte bridges are present 2, 44 ; and (iii) grafts of progenitor-derived astrocytes support axon regeneration through non-neural SCI lesion cores 45, 46 . The predominant mechanistic proposal for astrocytic scar inhibition of axon regeneration is CSPG production 9 . However, specific CSPGs can support or repel axon growth (see Extended Data Table 1 ). We show that scar-forming astrocytes upregulate growth supportive CSPG4 and CSPG5, and that both astrocytes and non-astrocytes in SCI lesions express multiple axon-growth-supportive molecules, including laminins. Axon growth and guidance depend both on intrinsic growth potential 2, 3, 31, 32, 47 and on a balance of extrinsic regulatory cues that modulate one another's effects on growth cones 25 . Our findings show that sustained delivery of required axon-specific growth factors not adequately expressed in SCI lesions, combined with activation of neuron-intrinsic growth programs, can stimulate robust regrowth of transected axons along specifically required supportive matrix cues in spite of the presence of inhibitory cues, and that this stimulated axon regrowth can occur either in direct contact with scar-forming astrocyte processes or independently of astrocyte processes. These observations provide direct evidence that the requirements for achieving axon regeneration across severe CNS lesions, where transected axons lack intrinsic and extrinsic conditions for long-distance regrowth, are fundamentally different from requirements to achieve local neurite outgrowth in intact but reactive perilesional grey matter, where conditions compatible with axon terminal growth and remodelling are present and where blocking inhibitory regulators such as CSPGs and others produced by astrocytes and other cells may be sufficient to promote axon sprouting that might also improve function 9, 15, 24, 28, 40, 48 . Our findings have important implications for CNS repair strategies by demonstrating that rather than being hostile to axon growth, newly generated immature scar-forming astrocytes derived after SCI from endogenous progenitors 18, 41, 44 , and potentially from grafted progenitors 45, 46 , aid axon regeneration and may represent exploitable bridges for regrowing axons across severe CNS lesions.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MeTHOdS
Mice. All non-transgenic, transgenic and control mice used in this study were derived from in house breeding colonies backcrossed > 12 generations onto C57/BL6 backgrounds. All mice used were young adult females between two and four months old at the time of spinal cord injury. All transgenic mice used have been previously well characterized or are the progeny of crossing well-characterized lines: (1) mGFAP-TK transgenic mice line 7.1 15, 16, 49 ; (2) mGFAP-Cre-STAT3-loxP mice generated by crossing STAT3-loxP mice with loxP sites flanking exon 22 of the STAT3 gene 50 with mGFAP-Cre mice line 73.12 17, 18 ; (3) loxP-STOPloxP-DTR (diphtheria toxin receptor) mice 21 ; (4) mGFAP-Cre-RiboTag mice generated by crossing mice with loxP-STOP-loxP-Rpl22-HA (RiboTag) 26 with mGFAP-Cre mice line 73.12 17, 18 ; (5) loxP-STOP-loxP-tdTomato reporter mice 51 . All mice were housed in a 12-h light/dark cycle in a specific-pathogen-free facility with controlled temperature and humidity and were allowed free access to food and water. All experiments were conducted according to protocols approved by the Animal Research Committee of the Office for Protection of Research Subjects at University of California, Los Angeles. Surgical procedures. All surgeries were performed under general anaesthesia with isoflurane in oxygen-enriched air using an operating microscope (Zeiss, Oberkochen, Germany), and rodent stereotaxic apparatus (David Kopf, Tujunga, CA). Laminectomy of a single vertebra was performed and severe crush spinal cord injuries (SCI) were made at the level of T10 using No. 5 Dumont forceps (Fine Science Tools, Foster City, CA) without spacers and with a tip width of 0.5 mm to completely compress the entire spinal cord laterally from both sides for 5 s [16] [17] [18] . For pre-conditioning lesions, sciatic nerves were transected and ligated one week before SCI. Hydrogels were injected stereotaxically into the centre of SCI lesions 0.6 mm below the surface at 0.2 μl per minute using glass micropipettes (ground to 50-100 μm tips) connected via high-pressure tubing (Kopf) to 10-μl syringes under control of microinfusion pumps, two days after SCI 52 . Tract tracing was performed by injection of biotinylated dextran amine 10,000 (BDA, Invitrogen) 10% wt/vol in sterile saline injected 4 × 0.4 μl into the left motor cerebral cortex 14 days before perfusion to visualize corticospinal tract (CST) axons, or choleratoxin B (CTB) (List Biological Laboratory, Campbell, CA) 1 μl of 1% wt/vol in sterile water injected into both sciatic nerves three days before perfusion to visualize ascending sensory tract (AST) axons 33 . AAV2/5-GfaABC1D-Cre (see below) was injected either 3 or 6 × 0.4 μl (1.29 × 10 13 gc ml −1 in sterile saline) into and on either side of mature SCI lesions two weeks after SCI, or into uninjured spinal cord after T10 laminectomy. All animals received analgesic before wound closure and every 12 h for at least 48 h post-injury. Animals were randomly assigned numbers and evaluated thereafter blind to genotype and experimental condition. AAV2/5-GfaABC1D-Cre. Adeno-associated virus 2/5 (AAV) vector with a minimal GFAP promoter (AAV2/5 GfaABC1D) was used to target Cre-recombinase expression selectively to astrocytes [53] [54] [55] . Hydrogel with growth factors and antibodies. Diblock co-polypeptide hydrogel (DCH) K 180 L 20 was fabricated, tagged with blue fluorescent dye (AMCA-X) and loaded with growth factor and antibody cargoes as described 38, 39, 52 . Cargo molecules comprised: human recombinant NT3 and BDNF were gifts (Amgen, Thousand Oaks, CA, (NT3 Lot#2200F4; BDNF Lot#2142F5A) or were purchased from PeproTech (Rocky Hill, NJ; NT3 405-03, Lot#060762; BDNF 405-02 Lot#071161). Function blocking anti-CD29 mouse monoclonal antibody was purchased from BD Bioscience (San Diego, CA) as a custom order at 10.25 mg ml ). DCH mixtures were prepared to have G′ (storage modulus at 1 Hz) between 75 and 100 Pascal (Pa), somewhat below that of mouse brain at 200 Pa (refs 38,39) . Ganciclovir (GCV), BrdU or DT injections. GCV (Cytovene-IV Hoffman LaRoche, Nutley, NJ), 25 mg kg −1 per day dissolved in sterile physiological saline was administered as single daily subcutaneous injections starting immediately after surgery and continued for the first 7 days after SCI. Bromodeoxyuridine (BrdU, Sigma), 100 mg kg −1 per day dissolved in saline plus 0.007 M NaOH, was administered as single daily intraperitoneal injections on days 2 through 7 after SCI. Diphtheria toxin A (DT, Sigma #DO564) 100 ng in 100 μl sterile saline was administered twice daily as intraperitoneal injections for ten days starting three weeks after injection of AAV2/5-GfaABC1D-Cre to loxP-DTR mice (which was 5 weeks after SCI) (see timeline in Extended Data Fig. 1d) . Hindlimb locomotor evaluation, animal inclusion criteria, randomization and blinding. Two days after SCI, all mice were evaluated in open field and mice exhibiting any hindlimb movements were not studied further. Mice that passed this pre-determined inclusion criterion were randomized into experimental groups for further treatments and were thereafter evaluated blind to their experimental condition. At 3, 7, 14 days and then weekly after SCI, hindlimb movements were scored using a simple six-point scale in which 0 is no movement and 5 is normal walking 17 . Histology and immunohistochemistry. After terminal anaesthesia by barbiturate overdose mice were perfused transcardially with 10% formalin (Sigma). Spinal cords were removed, post-fixed overnight, and cryoprotected in buffered 30% sucrose for 48 h. Frozen sections (30 μm horizontal) were prepared using a cryostat microtome (Leica) and processed for immunofluorescence as described [16] [17] [18] . Primary antibodies were: rabbit anti-GFAP (1:1,000; Dako, Carpinteria, CA); rat anti-GFAP (1:1,000, Zymed Laboratories); goat anti-CTB (1:1,000, List Biology Lab); rabbit anti-5HT (1:2,000, Immunostar); goat anti-5HT (1:1,000, Immunostar); mouse anti-CSPG 22 (1:100, Sigma); rabbit-anti haemagglutinin (HA) (1:500 Sigma); mouse-anti HA (1:3,000 Covance); sheep anti-BrdU (1:6,000, Maine Biotechnology Services, Portland, ME); rabbit anti-laminin ; Molecular Probes). Sections were coverslipped using ProLong Gold anti-fade reagent (InVitrogen, Grand Island, NY). Sections were examined and photographed using deconvolution fluorescence microscopy and scanning confocal laser microscopy (Zeiss, Oberkochen, Germany). Axon quantification. Axons labelled by tract tracing or immunohistochemistry were quantified using image analysis software (NeuroLucida, MicroBrightField, Williston, VT) operating a computer-driven microscope regulated in the x, y and z axes (Zeiss) by observers blind to experimental conditions. Using NeuroLucida, lines were drawn across horizontal spinal cord sections at SCI lesion centres and at regular distances on either side (Fig. 1a) and the number of axons intercepting lines was counted at 63× magnification under oil immersion by observers blind to experimental conditions. Similar lines were drawn and axons counted in intact axon tracts 3 mm proximal to SCI lesions and the numbers of axon intercepts in or near lesions were expressed as percentages of axons in the intact tracts in order to control for potential variations in tract-tracing efficacy or intensity of immunohistochemistry among animals. Two sections at the level of the CST or AST, and three sections through the middle of the cord for 5HT, were counted per mouse and expressed as total intercepts per location per mouse. To determine efficacy of axon transection after SCI, we examined labelling 3 mm distal to SCI lesion centres, with the intention of eliminating mice that had labelled axons at this location on grounds that these mice may have had incomplete lesions. However, all mice that had met the strict behavioural inclusion criterion of no hindlimb movements two days after severe crush SCI, exhibited no detectable axons 3 mm distal to SCI lesions regardless of treatment group. Quantification of immunohistochemically stained areas. Sections stained for GFAP, CSPG or laminin were photographed using constant exposure settings. Single-channel immunofluorescence images were converted to black and white and thresholded (Fig. 1d and Extended Data Fig. 2b ) and the amount of stained area measured in different tissue compartments using NIH ImageJ software. Areas are shown in graphs as mean values plus or minus standard error of the means (s.e.m.). Statistics, power calculations and group sizes. Statistical evaluations of repeated measures were conducted by ANOVA with post hoc, independent pairwise analysis as per Newman-Keuls (Prism, GraphPad, San Diego, CA). Power calculations were performed using G*Power Software v3.1.9.2 (ref. 57) . For quantification of histologically derived neuroanatomical outcomes such as numbers of axons or percentage of area stained for GFAP or CSPG, group sizes were used that were calculated to provide at least 80% power when using the following parameters: probability of type I error (α) = 0.05, a conservative effect size of 0.25, 2-8 treatment groups with multiple measurements obtained per replicate. Using Fig. 5j as an example, evaluation of n = 5 biological replicates (with multiple measurements per replicate) in each of 8 treatment groups provided greater than 88% power. Dot blot. For dot blot immunoassay of chondroitin sulfate proteoglycans (CSPG), spinal cord tissue blocks were lysed and homogenized in standard RIPA (radio-immunoprecipitation assay) buffer. LDS (lithium dodecyl sulfate) buffer (Life Technologies) was added to the post-mitochondrial supernatant and 2 μl containing 2 μg μl −1 protein was spotted onto a nitrocellulose membrane Article reSeArcH (Life Technologies), set to dry and incubated overnight with mouse antichondroitin sulfate antibody (CS56, 1:1000, Sigma Aldrich), an IgM-monoclonal antibody that detects glyco-moieties of all CSPGs 22 . CS56 immunoreactivity was detected on X-ray film with alkaline phosphatase-conjugated secondary antibody and chemiluminescent substrate (Life Technologies). Densitometry measurements of CS56 immunoreactivity were obtained using ImageJ software (NIH) and normalized to total protein (Poncau S) density 58 . Densities are shown in graphs as mean values plus or minus standard error of the means (s.e.m.). Isolation, sequencing and analysis of RNA from astrocytes and non-astrocyte cells. Two weeks after SCI, spinal cords of wild-type control (GFAP-RiboTag) and STAT3-CKO (GFAP-STAT3CKO-RiboTag) mice were rapidly dissected out of the spinal canal. The central 3 mm of the lower thoracic lesion including the lesion core and 1 mm rostral and caudal were then rapidly removed and snap frozen in liquid nitrogen. Haemagglutinin (HA) immunoprecipitation (HA-IP) of astrocyte ribosomes and ribosome-associated mRNA (ramRNA) was carried out as described 26 . The non-precipitated flow-through (FT) from each IP sample was collected for analysis of non-astrocyte total RNA. HA and FT samples underwent on-column DNA digestion using the RNase-Free Dnase Set (Qiagen) and RNA purified with the RNeasy Micro kit (Qiagen). Integrity of the eluted RNA was analysed by a 2100 Bioanalyzer (Agilent) using the RNA Pico chip, mean sample RIN = 8.0 ± 0.95. RNA concentration determined by RiboGreen RNA Assay kit (Life Technologies). cDNA was generated from 5 ng of IP or FT RNA using the Nugen Ovation 2 RNA-Seq Sytstem V2 kit (Nugen). 1 μg of cDNA was fragmented using the Covaris M220. Paired-end libraries for multiplex sequencing were generated from 300 ng of fragmented cDNA using the Apollo 324 automated library preparation system (Wafergen Biosystems) and purified with Agencourt AMPure XP beads (Beckman Coulter). All samples were analysed by an Illumina NextSeq 500 Sequencer (Illumina) using 75-bp paired-end sequencing. Reads were quality controlled using in-house scripts including picard-tools, mapped to the reference mm10 genome using STAR 59 , and counted using HT-seq 60 with mm10 refSeq as reference, and genes were called differentially expressed using edgeR 
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Extended Data Figure 4 | Comparison of genomic data from astrocytes and non-astrocyte cells from WT and STAT3-CKO mice after SCI. a, Heat maps depicting all significantly differentially expressed genes (DEG), as determined by RNA-seq, for wild-type (WT) and STAT3-CKO astrocytes and non-astrocytes from independent biological replicates two weeks after SCI relative to uninjured wild-type control. Red upregulated, green downregulated. b, Total numbers and Venn diagrams of significant DEGs in wild-type and STAT3-CKO astrocytes and non-astrocytes two weeks after SCI relative to uninjured control. Red and green numerical values indicate significantly upregulated and downregulated genes, respectively. c, Comparison of altered gene expression in our SCI-reactive astrocytes and previously reported forebrain stroke-reactive astrocytes 27 .
Of the 200 most highly elevated genes in forebrain astrocytes one week following stroke 27 , 58.5% (red line) are also significantly elevated in astrocytes after SCI, relative to uninjured. d, Comparison of expression by wild-type SCI and STAT3-CKO SCI reactive astrocytes of a selected crosssection of genes that are highly regulated after SCI by wild-type reactive astrocytes. Many of the regulated genes exhibit changes that are expected and implicated in wild-type reactive astrogliosis mechanisms and roles, and some of the changes appear to be newly identified in this context. Note that many of the genes are not regulated or exhibit attenuated changes in STAT3-CKO SCI astrocytes. n = 4 mice each for uninjured and wildtype SCI; n = 3 mice for STAT3-CKO SCI (SCI-STAT3). FDR < 0.1 for differential expression and enrichment analysis.
